US Smoking Cessation Clinical Trials Guidance ‘Does Not Envision’ Flexibility On Indications

FDA final guidance maintains limit on secondary endpoints allowed for trials, which could dissuade some investment in research for NDAs for smoking cessation products. NRT developers could find more room for novel product proposals from changes to some phrasing.